Agenus Inc
$ 6.96
-7.08%
07 Aug - close price
- Market Cap 289,831,000 USD
- Current Price $ 6.96
- High / Low $ 7.55 / 6.92
- Stock P/E 3.40
- Book Value -5.74
- EPS 2.05
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE -12.79 %
- 52 Week High 8.85
- 52 Week Low 2.71
About
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$22.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-11 | 2026-03-16 | 2025-11-10 | 2025-08-11 | 2025-05-12 | 2025-03-11 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-03-14 | 2023-11-07 |
| Reported EPS | 1 | -0.03 | 0.6808 | -1.16 | -1 | -1.03 | -2.04 | -3.08 | -2.52 | -3.04 | -0.13 | -3.2 |
| Estimated EPS | 0.05 | 1.8 | -1.3 | 2.2 | 1.35 | -1.98 | -2.542 | -2.31 | -1.33 | -3.22 | -0.05 | -3.95 |
| Surprise | 0.95 | -1.83 | 1.9808 | -3.36 | -2.35 | 0.95 | 0.502 | -0.77 | -1.19 | 0.18 | -0.08 | 0.75 |
| Surprise Percentage | 1900% | -101.6667% | 152.3692% | -152.7273% | -174.0741% | 47.9798% | 19.7482% | -33.3333% | -89.4737% | 5.5901% | -160% | 18.9873% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGEN
2026-08-08 12:40:00
This page provides news and analysis for Agenus Inc (AGEN) stock, a company in the Biotechnology & Medical Research sector. It lists the current stock price, market cap, and P/E ratio, alongside links to financial data, ownership, dividends, and discussions. The news section highlights a previous article about Bristol-Myers Squibb Co (BMY) stock performance.
2026-08-08 12:39:59
AGENUS INC reported a strong second quarter for 2026, with revenue reaching $34.5 million, a 34.3% increase year-over-year. The company achieved a net income of $38.6 million for the year-to-date, contrasting sharply with a loss in the prior year, and diluted EPS of $0.96. These results were driven by strategic initiatives in clinical development, expanded commercial access, and operational changes to extend their cash runway.
2026-08-07 21:09:33
Agenus Inc. has filed to resell up to 78 million shares. This announcement follows recent positive news for the company, including strong second-quarter earnings, a price target adjustment from B. Riley, and significant funding from RA Capital Management, L.P. The biotech company is focused on immuno-oncology and recently reported promising three-year Phase 1b data for its colorectal cancer combination therapy.
2026-08-07 20:42:00
Agenus Inc. (AGEN) reported a second-quarter loss of $550,000, translating to 1 cent per share. The biotechnology company achieved $34.5 million in revenue for the period. Agenus shares have more than doubled since the start of the year, with a 46% increase in the last 12 months, closing at $6.96 on Friday.
2026-08-07 18:09:33
Agenus Inc. has awarded 50,000 stock options to director Timothy Wright under its 2019 Amended and Restated Equity Incentive Plan. The options have an exercise price of $7.78 per share, expire on August 5, 2036, and will vest over three years. This grant aims to align the director's interests with the company's long-term performance.
2026-08-07 18:09:33
AGENUS INC (AGEN) has granted 100,000 stock options to its Chief Medical Officer, Steven J. O'Day, on August 5, 2026. These options have an exercise price of $7.7800 per share and will expire on August 5, 2036. The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remainder vesting in two equal annual installments.
